2025
The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung H, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Frontiers In Immunology 2025, 16: 1495529. PMID: 40443664, PMCID: PMC12119304, DOI: 10.3389/fimmu.2025.1495529.Peer-Reviewed Original ResearchConceptsBruton tyrosine kinase inhibitorCentral nervous systemTyrosine kinase inhibitorsBruton's tyrosine kinaseMagnetic resonance imagingPositron emission tomographyMultiple sclerosisMicroglial functionPrimary resident immune cellsTissue repairNeural homeostasisPathogenesis of MSPathophysiology of MSResident immune cellsChronic autoimmune diseaseCentral nervous system developmentInvolvement of microgliaPotential therapeutic strategyModulating microglial functionDisease progression rateImmune surveillanceImprove patient outcomesImmune cellsAutoimmune diseasesProgressive MS
2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.
Huntington S, Rhodes J, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Marx S, Doshi J. Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia. JCO Oncology Practice 2024, op2400220. PMID: 39705617, DOI: 10.1200/op.24.00220.Peer-Reviewed Original ResearchChronic lymphocytic leukemia treatmentChronic lymphocytic leukemiaFollow-up periodFrontline settingLymphocytic leukemiaTreatment patternsFollow-upReal-world treatment patternsMedian time to discontinuationBruton tyrosine kinase inhibitorAnti-CD20 monotherapyPatients discontinued treatmentMonths of treatmentTime to discontinuationTyrosine kinase inhibitorsReal-world studyPatient-monthsBTKiTreatment optionsVenetoclaxKinase inhibitorsPatientsAll-CauseBcl-2Months156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataBCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review
Feng S, Xiong Y, Liu W, Liu H, Sui W, Zheng P, Sun M, Hu K, Zhang Y. BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review. Critical Reviews In Oncology/Hematology 2024, 205: 104551. PMID: 39510436, DOI: 10.1016/j.critrevonc.2024.104551.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaPlasmablastic lymphomaCAR-TLymphocytic leukemiaTransformation of chronic lymphocytic leukemiaCAR-T cell treatmentBruton tyrosine kinase inhibitorPatient's chronic lymphocytic leukemiaRight supraclavicular massNovel targeted agentsTyrosine kinase inhibitorsRichter transformationSupraclavicular massBrentuximab vedotinTargeted therapyTargeted agentsRare caseBone marrowCase reportTherapy choiceKinase inhibitorsInnovative therapiesCell treatmentTherapyBCMAReal-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00569-x.Peer-Reviewed Original ResearchCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinibReal-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Huntington S, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1106-1116. PMID: 39046941, PMCID: PMC11424914, DOI: 10.18553/jmcp.2024.24049.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMonths 0Frontline settingSample of older US adultsMedicare beneficiariesLymphocytic leukemiaFee-for-service Medicare beneficiariesTreatment periodStudy of older adultsTyrosine kinase inhibitor useOlder US adultsBruton tyrosine kinase inhibitorFixed-duration therapyUS Medicare beneficiariesFee-for-serviceMonthly costTyrosine kinase inhibitorsHealth care costsMedicare Part ABcl-2 inhibitorsMultivariate general linear modelMonthly total costsTotal monthly costsPrescription drug costsComparison of health care costsReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-CauseNovel therapeuticsEconomic burdenSurvivalReal-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, De Nigris E. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 2024, 65: 932-942. PMID: 38696747, DOI: 10.1080/10428194.2024.2331631.Peer-Reviewed Original ResearchSequential targeted therapyLymphocytic lymphomaTherapy useB-cell lymphoma 2 inhibitorChronic lymphocytic leukemia/small lymphocytic lymphomaBruton tyrosine kinase inhibitorTargeted therapy useSmall lymphocytic lymphomaChronic lymphocytic leukemiaTyrosine kinase inhibitorsProportion of patientsClaims-based studyFirst-lineLymphocytic leukemiaTargeted therapyClinical outcomesB cellsKinase inhibitorsTreatment sequenceReal-world patternsTherapyCLL/SLLBTKiCD20LymphomaA review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Airas L, Bermel R, Chitnis T, Hartung H, Nakahara J, Stuve O, Williams M, Kieseier B, Wiendl H. A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis. Therapeutic Advances In Neurological Disorders 2024, 17: 17562864241233041. PMID: 38638671, PMCID: PMC11025433, DOI: 10.1177/17562864241233041.Peer-Reviewed Original ResearchBruton tyrosine kinase inhibitorChronic spontaneous urticariaFirst-generation BTK inhibitorSystemic lupus erythematosusBruton's tyrosine kinaseTyrosine kinase inhibitorsMS disease-modifying treatmentsBTK inhibitorsDisease-modifying treatmentsSafety profileB cellsMultiple sclerosisChronic useRheumatoid arthritisSecond-generation BTK inhibitorsB cell depletion therapyTreatment of B-cell malignanciesB-cell modulationDiverse autoimmune conditionsPhase II trialGadolinium-enhancing lesionsB-cell malignanciesMagnetic resonance imaging scansLong-term administrationFemale reproductive health
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply